ASCAT 2025 Top Abstracts Showcase
| Wednesday, October 1, 2025 |
| 4:40 PM - 6:30 PM |
| Main Plenary Hall - Rooms 8 & 11 |
Overview
Chair:Raffaella Colombatti
Speakers:
Dr Stella Malangahe - Preliminary results of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Tanzania
Prof. Biree Andemariam - Voxelotor Safety and Effectiveness in Patients With SCD in the RETRO and PROSPECT US Registries
Prof. Halima Bello-Manga - Phase 3, Randomized, HOPE Kids-2 Trial of Voxelotor in Children with SCD and Conditional TCD
Prof. Halima Bello-Manga - RESOLVE: a Phase 3, Randomized Trial Evaluating Voxelotor for Leg Ulcer Healing in SCD
Prof. Khaled Musallam - Survival and Morbidity Among Adults With Thalassemia in England: Retrospective Analysis Using Routine Healthcare Data
Prof. Josu de la Fuente - Durable Clinical Benefits With Exagamglogene Autotemcel for Transfusion-dependent Thalassemia and Severe Sickle Cell Disease
Dr Kofi Anie - Patient Advocacy Group Involvement in the Development of the MANAGE, MONITOR, REALIZE (MMR) Framework
Main Plenary Hall - Rooms 8 & 11
Presenters
Prof. Raffaella Colombatti
Associate Professor Of Pediatrics
University of Padova
Session Chair
Dr Stella Malangahe
Hematologist
Benjamin Mkapa Hospital
Preliminary results of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Tanzania
Prof. Biree Andemariam
Professor Of Medicine
University Of Connecticut Health
Voxelotor Safety and Effectiveness in Patients With SCD in the RETRO and PROSPECT US Registries
Prof. Halima Bello-Manga
Assistant Professor
Barau Dikko Teaching Hospital, Kaduna State University
Phase 3, Randomized, HOPE Kids-2 Trial of Voxelotor in Children with SCD and Conditional TCD
Prof. Halima Bello-Manga
Assistant Professor
Barau Dikko Teaching Hospital, Kaduna State University
RESOLVE: a Phase 3, Randomized Trial Evaluating Voxelotor for Leg Ulcer Healing in SCD
Prof. Khaled Musallam
Group Chief Research Officer, Director Thalassemia & Sickle Cell Center
Burjeel Medical City
Survival and Morbidity Among Adults With Thalassemia in England: Retrospective Analysis Using Routine Healthcare Data
Prof. Josu de la Fuente
Consultant haematologist
Imperial College Healthcare NHS Trust, St Mary’s Hospital
Durable Clinical Benefits With Exagamglogene Autotemcel for Transfusion-dependent Thalassemia and Severe Sickle Cell Disease
Dr Kofi Anie
Psychologist
London Northwest University Healthcare NHS Trust
Patient Advocacy Group Involvement in the Development of the MANAGE, MONITOR, REALIZE (MMR) Framework
